BioSupply UK
← Back to Insights
Ipamorelin and CJC-1295 — What Does the Research Say About This GHRP/GHRH Pairing?
Research Science615 September 2026

Ipamorelin and CJC-1295 — What Does the Research Say About This GHRP/GHRH Pairing?

Ipamorelin and CJC-1295 target two different arms of the growth-hormone axis, which is why they appear together so often in the research literature.

Two different mechanisms

Ipamorelin and CJC-1295 are usually discussed as a pair because they act on complementary receptors in the growth-hormone (GH) axis:

  • Ipamorelin is a pentapeptide ghrelin receptor agonist (a GH secretagogue, or GHRP). In pituitary cell models it stimulates pulsatile GH release, and it is noted in the literature for its selectivity — early studies reported little effect on cortisol or prolactin compared with older GHRPs.
  • CJC-1295 (without DAC), also called Mod GRF 1-29, is a modified fragment of growth-hormone-releasing hormone (GHRH). It works on the GHRH receptor — the other arm of the same axis.

Because the two peptides act on different receptors, preclinical studies have examined whether combining them produces additive or synergistic GH pulses in animal models — a question that drives the pairing's prominence in research catalogues.

Research themes

  • Pulsatility studies — how secretagogue timing affects natural GH pulse architecture in rodent models.
  • Receptor selectivity — Ipamorelin's clean receptor profile makes it a common reference compound in ghrelin-receptor assays.
  • IGF-1 response — downstream insulin-like growth factor changes are a standard endpoint in GHRH-analogue studies.

Related compounds

Researchers comparing secretagogues may also encounter Tesamorelin, a stabilised GHRH analogue that — unusually for this class — holds FDA approval for a specific clinical indication, making its published human data far deeper than most peptides in this category.

Sourcing for research

BioSupply UK stocks Ipamorelin and a combined CJC-1295 (No DAC) / Ipamorelin vial, both HPLC and mass-spec verified with Certificates of Analysis.

Summary

The Ipamorelin + CJC-1295 pairing is a textbook example of two-receptor targeting within one hormonal axis, and that mechanistic elegance keeps it central to GH-axis research. Clinical evidence in humans remains limited, and neither compound is an approved medicine.

All products mentioned are supplied strictly for laboratory research purposes only and are not intended for human consumption, diagnosis, or treatment. Nothing in this article constitutes medical advice.

Comments

No comments yet. Be the first to leave one!

Leave a Comment

Your email will not be published. Comments are moderated.